Phase 1 study of fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis. J of Skin. 2023;7(2):s179. doi:10.25251/skin.7.supp.179